6550-- Ventena Contract Request
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), Network Contracting Office 17, has awarded a Firm-Fixed-Price Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Roche Diagnostics Corporation for Ventana reagents and consumable supplies. This sole-source award, valued at up to $1.4 million, supports the North Texas Health Care System's Pathology & Laboratory Medicine Service by ensuring the continued operation of their Ventana BenchMark Ultra/HE600 systems. The award date was April 21, 2026.
Scope of Work
The contract covers the provision of approximately 40 specific Ventana reagents and consumable supplies. These items, including various reagents (e.g., DAB Detection, Hematoxylin), staining kits (e.g., Elastin Van Gieson), antibodies (e.g., Confirm Cytokeratin7, KI 67), and IHC ancillaries, are proprietary and exclusively compatible with the government-owned Ventana BenchMark Ultra/HE600 systems. Supplies will be ordered on an as-needed basis.
Contract Details
- Awardee: Roche Diagnostics Corporation
- Type: Firm-Fixed-Price IDIQ
- Value: Up to $1,400,000.00 (ceiling)
- Duration: Five one-year ordering periods, from approximately April 19, 2026, through April 18, 2031.
- Award Date: April 21, 2026
- Set-Aside: None (Sole Source)
- Justification: Awarded under "Other Than Full and Open Competition" (FAR 6.302-1, Only One Responsible Source) due to the proprietary nature of Ventana products and their exclusive compatibility with existing VA equipment. Market research and a sole-source letter from Roche confirmed no known substitutes.
Background
The VA previously issued a Special Notice of Intent to Award a Sole Source Procurement. All responsible sources were invited to submit capability statements, proposals, or quotations to determine if a comparable and more advantageous source was available. Only Roche Diagnostics Corporation responded to this notice, leading to the final award.